SKP2 overexpression has been found in a wide range of human malignancies, including lymphomas (142), prostate cancer (143), colorectal cancer (144), melanoma (145), nasopharyngeal carcinoma (146), pancreatic cancer (147), and breast carcinomas (148). Here, SKP2 is linked to prostate carcinoma.